Dtf & Dtf 1 Te E Gyan May 19

The given answer "Smarter Safer Superior" is the correct answer because it matches the given options. The options include the words "Smarter," "Safer," and "Superior," and the correct answer includes all three of these words.

The correct answer is "A promise to Protect." This suggests that the brand, Telrose, is making a commitment to protect something. Based on the context provided, it can be inferred that Telrose is promising to protect both the heart (CardioProtection) and the kidneys (Renal Protection). Therefore, the brand is offering Cardiorenal protection as part of its brand promise.

The brand promise of Meconerv Plus is to recharge nerves for smooth conduction. This suggests that the product is designed to improve the functioning of nerves and ensure that signals are transmitted effectively throughout the body. By using Meconerv Plus, individuals may experience improved nerve function, which can have a positive impact on overall health and well-being. This promise is reinforced by the statement "Recharge with Complete Nerve Antioxidant," indicating that the product contains antioxidants that support nerve health. Additionally, the mention of specific conditions like hypertension, diabetes, and cognitive decline suggests that Meconerv Plus may be beneficial for individuals with these health concerns.

Pioglitazone is an insulin sensitiser. It belongs to a class of oral hypoglycemic agents called thiazolidinediones, which work by increasing the body's sensitivity to insulin. This helps to improve glucose control in individuals with type 2 diabetes by allowing insulin to work more effectively in lowering blood sugar levels. Glinides, Acarbose, and Miglitol are not insulin sensitizers, but rather work through different mechanisms to help control blood sugar levels.

The correct answer is "Scores on Total Neuropathy Care." This suggests that Pregator, as a brand, promises to provide high scores or ratings in terms of its total care for neuropathy. This implies that Pregator is committed to offering comprehensive and effective care for individuals suffering from neuropathy, ensuring their overall well-being and satisfaction.

Product wise incentives are released annually. This means that employees or salespeople receive incentives or bonuses based on the sales or performance of specific products on a yearly basis. This can be a motivating factor for individuals to work hard and achieve their targets throughout the year, knowing that they will be rewarded at the end of it. Releasing incentives annually also allows for a comprehensive evaluation of performance and ensures that the rewards are distributed fairly and accurately.

The correct answer is "All of the Above" because microvascular complications can lead to neuropathy and retinopathy. Microvascular complications refer to damage to the small blood vessels in the body, which can affect various organs and tissues. Neuropathy is a condition that affects the nerves, often resulting in numbness, tingling, and pain. Retinopathy is a condition that affects the blood vessels in the retina of the eye, leading to vision problems. Therefore, all of these conditions can be considered as microvascular complications.

The statement suggests that in order to earn call average, compliance, and RCPA Norms incentive, there should not be negative growth. Additionally, the disbursement will be done quarterly according to the reporting schedule set by the company. Therefore, the correct answer is true.

The correct answer is Rs. 500 - Achieve 70% of your sales by 21st of the month. This option offers the highest sales target among the given choices, indicating that the sales target is expected to be higher for this option compared to the others. Additionally, achieving 70% of the sales target by the 21st of the month suggests that there is a sense of urgency to close sales early in the month.

The correct answer is "All of the Above" because all of the listed conditions can contribute to the development of congestive heart failure (CHF). Hypertension (HTN) and coronary artery disease (CAD) can lead to the weakening of the heart muscle and impaired pumping function. Cardiomyopathy refers to diseases of the heart muscle, which can also result in CHF. Valvular heart disease and adult congenital heart disease can cause abnormalities in the heart valves, leading to increased pressure and strain on the heart, eventually leading to CHF. Therefore, all of these conditions can be potential causes of CHF.

If the PCPM (Per Capita Per Month) is 2.5 Lac (250,000) and the growth is greater than or equal to 30%, the incentive that TE (presumably a person or entity) will earn is 8400.

The symptoms of left ventricular hypertrophy (LVH) include increasing shortness of breath with activity and while lying flat, cough, palpitations, fatigue, decreased urine production, and waking in the middle of the night with difficulty breathing. Therefore, the correct answer is "All of the Above" as all these symptoms are associated with LVH.

The correct answer is Rs. 500 - Minimum 90% visit compliance of all core doctors (2/3 visits) as defined by division. This option offers a lower incentive compared to the other options, indicating that it is the minimum requirement for visit compliance. It specifies that at least 90% of the core doctors must comply with the minimum visit requirement of 2 out of 3 visits as defined by the division.

The correct answer is ID & IR, which stands for Insulin Deficiency and Insulin Resistance. These two factors play a significant role in the development of Type 2 diabetes. Insulin is a hormone that helps regulate blood sugar levels, and when there is a deficiency of insulin or the body becomes resistant to its effects, it can lead to elevated blood sugar levels and the development of diabetes. Insulin deficiency occurs when the pancreas does not produce enough insulin, while insulin resistance happens when the body's cells do not respond properly to insulin. Both of these factors contribute to the development of Type 2 diabetes.

Dipeptidyl Peptidase: IV inhibitors (DPP-IV inhibitors) such as Sitagliptin, Saxagliptin, Vildagliptin, and Linagliptin work by decreasing the breakdown of GLP-1 (Glucagon like Peptide) in the body. This results in an extended half-life of endogenous GLP-1, which helps in reducing postprandial blood glucose levels. By inhibiting the breakdown of GLP-1, these drugs enhance its effect in regulating blood sugar levels and can be effective in managing diabetes.

The growth is calculated by taking the difference between the current year's sales (CYS) and the previous year's sales (LYS), divided by the previous year's sales (LYS), and then multiplying by 100. This formula measures the percentage change in sales from one year to the next, indicating the growth rate.

If TE achieves 1.3 Cr annually with a 25% growth, they will receive an incentive of 3 lac. This means that if their annual revenue reaches 1.3 Cr and grows by 25%, the incentive they will receive is 3 lac.

The correct answer is "All of the Above". This means that all of the statements mentioned in the question are true. Telrose has a unique selling proposition (USP) which includes improving patient compliance, being pro equivalent to co-administration of separate tablets, and decreasing HOMA-IR by 29% and hr-CRP by 44%.

If the TE sale is 24 Lac in one year, then the TE will be eligible to receive an annual incentive of 30 K Utility Item.

The correct answer explains that Glinides, including Repaglinide, Mitiglinide, and Nataglinide, are short-acting agents that work similarly to sulphonylureas as insulin secretagogues. They are effective in reducing postprandial blood glucose levels. This means that they help stimulate the release of insulin from the pancreas, which helps to lower blood sugar levels after a meal.

Alphaglucosidase inhibitors such as Voglibose, Acarbose, and Miglitol work by reversibly and competitively inhibiting the alpha glucosidase enzymes. These enzymes are responsible for breaking down and absorbing carbohydrates in the body. By inhibiting these enzymes, these drugs reduce the rate at which carbohydrates are broken down and absorbed, leading to a decrease in postprandial blood glucose levels. This mechanism of action is different from drugs that reduce insulin resistance or act on insulin resistance at peripheral cells. Additionally, alphaglucosidase inhibitors do not have a lipid-lowering profile.

The answer is Rs. 500 because it offers the lowest price while still meeting the minimum requirement of 90% of expected 300 doctor calls in the month. This option provides the best value for meeting the required target.

The given answer states that the minimum amount for core and targeted doctors is Rs. 500. This means that when filling the RCPA (prescription forms), detailing of brands, distributing samples and gifts, and POBS (promotion of brand strategy) to core and targeted doctors, the minimum amount spent should be Rs. 500. This amount does not include chemists, stockists, or c&f (carrying and forwarding agents).

If TE achieves a sale of 48 lac with a 30% growth and also hits the target for 2019-20 with a base sale of 37 lac in 2018-19, then TE can earn a total incentive of 4.65 Lac. This can be calculated by first finding the growth amount, which is 48 lac - 37 lac = 11 lac. Then, finding the incentive for the growth amount by multiplying it with the incentive rate of 0.15 (15% of the growth amount), which is 11 lac * 0.15 = 1.65 Lac. Finally, adding the incentive for hitting the target (3 Lac) with the incentive for the growth amount, the total incentive earned is 3 Lac + 1.65 Lac = 4.65 Lac.

The correct answer is 13702. Based on the given information, TE PCPM is 3.80 lac (3,80,000) and the growth is greater than or equal to 25%. The total earning of incentive can be calculated by multiplying the TE PCPM by the growth percentage (25%) and then adding it to the TE PCPM. Therefore, the calculation would be 3,80,000 + (3,80,000 * 25%) = 3,80,000 + 95,000 = 4,75,000. However, since the given options do not include this exact amount, the closest option is 13702.

The correct answer is the explanation provided in the question. Atherosclerosis is indeed the reduction in blood flow through the arteries caused by plaque buildup on the artery walls, leading to partial restriction of blood flow. This condition is commonly known as hardening of the arteries, and it causes the arteries to thicken, harden, and lose their elasticity. As a result, the heart has to work harder to pump blood through the narrowed arteries.

All of the above options, Glimepride, Glibenclamide, and Gliclazide, are Sulphonyl Urea drugs that have been found to have cardioprotective effects. These drugs are commonly used to treat diabetes by lowering blood sugar levels. However, studies have shown that they also have additional benefits in protecting the heart from damage caused by various cardiovascular conditions. Therefore, all of these drugs can be considered as cardioprotective Sulphonyl Urea medications.

Based on the given information, if the PCPM (Per Capita Per Month) is 1.5 Lac and the growth is greater than or equal to 35%, the incentive that TE (presumably a person or entity) will receive is 3150.

The incentive TE will receive is 20900. This can be determined by multiplying the PCPM (4.75) by the growth percentage (>30%). By multiplying 4.75 by 1.3, we get 6.175. Multiplying this by 3400 (the base incentive amount), we get 20900.

The incentive amount for TE will be 49500. This can be determined by multiplying the PCPM (9 Lac) by the growth percentage (12.5%) and then adding the result to the PCPM. This calculation would give us an incentive amount of 49500.